NCT02650843

Brief Summary

This project aims to clarify the role non-motor symptoms in the development of Parkinson's disease (PD) and to improve diagnostics at very early stages of PD. The project involves multidimensional measures of disease biomarkers together with brain dopamine transporter (DAT) imaging with \[123I\]FP-CIT single photon emission computed tomography (SPECT).

Trial Health

83
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
455

participants targeted

Target at P75+ for all trials

Timeline
7mo left

Started Jan 2015

Longer than P75 for all trials

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress95%
Jan 2015Dec 2026

Study Start

First participant enrolled

January 1, 2015

Completed
1 year until next milestone

First Submitted

Initial submission to the registry

January 5, 2016

Completed
3 days until next milestone

First Posted

Study publicly available on registry

January 8, 2016

Completed
10.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2026

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2026

Last Updated

April 13, 2025

Status Verified

April 1, 2025

Enrollment Period

11.9 years

First QC Date

January 5, 2016

Last Update Submit

April 11, 2025

Conditions

Parkinson DiseaseParkinsonism

Keywords

ParkinsonismDAT Dopamine transporterSPECT

Outcome Measures

Primary Outcomes (1)

  • DAT SPECT striatal specific binding ratio

    Up to 10 years

Study Arms (1)

Patients with parkinsonism

Patients with parkinsonism that are referred for DAT SPECT imaging in Turku University Hospital, Finland or Helsinki University Hospital, Finland

Other: DAT SPECT imaging

Interventions

DAT SPECT imagingOTHER
Patients with parkinsonism

Eligibility Criteria

Age18 Years - 100 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with parkinsonism

You may qualify if:

  • Male or Female
  • Age 18-100 years
  • Referred for clinical DAT SPECT in Turku or Helsinki

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (2)

  • Eklund M, Nuuttila S, Joutsa J, Jaakkola E, Makinen E, Honkanen EA, Lindholm K, Vahlberg T, Noponen T, Ihalainen T, Murtomaki K, Nojonen T, Levo R, Mertsalmi T, Scheperjans F, Kaasinen V. Diagnostic value of micrographia in Parkinson's disease: a study with [123I]FP-CIT SPECT. J Neural Transm (Vienna). 2022 Jul;129(7):895-904. doi: 10.1007/s00702-022-02517-1. Epub 2022 May 27.

    PMID: 35624405DERIVED

  • Nuuttila S, Eklund M, Joutsa J, Jaakkola E, Makinen E, Honkanen EA, Lindholm K, Noponen T, Ihalainen T, Murtomaki K, Nojonen T, Levo R, Mertsalmi T, Scheperjans F, Kaasinen V. Diagnostic accuracy of glabellar tap sign for Parkinson's disease. J Neural Transm (Vienna). 2021 Nov;128(11):1655-1661. doi: 10.1007/s00702-021-02391-3. Epub 2021 Jul 30.

    PMID: 34328563DERIVED

MeSH Terms

Conditions

Parkinson DiseaseParkinsonian Disorders

Condition Hierarchy (Ancestors)

Basal Ganglia DiseasesBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesMovement DisordersSynucleinopathiesNeurodegenerative Diseases

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER GOV
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 5, 2016

First Posted

January 8, 2016

Study Start

January 1, 2015

Primary Completion (Estimated)

December 1, 2026

Study Completion (Estimated)

December 1, 2026

Last Updated

April 13, 2025

Record last verified: 2025-04